ImmunityBio (NASDAQ:IBRX) Trading Up 15.2% – What’s Next?

ImmunityBio, Inc. (NASDAQ:IBRX) shot up 15.2% during trading on Tuesday . The stock traded as high as $7.76 and last traded at $7.67. 23,811,974 shares changed hands during mid-day trading, a decline of 39% from the average session volume of 39,122,590 shares. The stock had previously closed at $6.66.

Key Stories Impacting ImmunityBio

Here are the key news stories impacting ImmunityBio this week:

• Positive Sentiment: Company raised ~$100M for global expansion, a near‑term liquidity boost that can support operations and development. ImmunityBio (IBRX) Rallies 15% as Firm Raises $100M For Global Expansion
• Positive Sentiment: Company reported its strongest quarter ever per media coverage, which investors may view as operational momentum despite the controversy. IBRX stock notches strongest quarter ever
• Neutral Sentiment: Multiple law firms are issuing investor alerts and invitations to join or lead class actions — procedural notices that increase public attention and could accelerate filings but do not by themselves change the company’s legal exposure. (Examples: Robbins Geller, Kessler Topaz, Faruqi, Pomerantz, Rosen, Levi & Korsinsky.) Robbins Geller investor notice
• Negative Sentiment: FDA issued a warning letter finding some promotional statements about Anktiva misleading; that regulatory finding triggered a major sell‑off (reported ~21% decline and ~$2B market‑cap loss) and is the core allegation in ensuing securities lawsuits. That materially raises regulatory and litigation risk. Hagens Berman on FDA warning and share plunge
• Negative Sentiment: Several securities‑fraud class actions have been filed (and many firms are soliciting lead‑plaintiff applicants) alleging material misstatements/omissions about Anktiva between Jan 19 and Mar 24, 2026; potential damages and legal costs pose downside risk and could distract management. Kessler Topaz class action announcement

Analyst Ratings Changes

A number of equities analysts recently weighed in on the stock. BTIG Research assumed coverage on shares of ImmunityBio in a report on Thursday, March 12th. They set a “buy” rating and a $13.00 target price on the stock. The Goldman Sachs Group restated a “buy” rating on shares of ImmunityBio in a research note on Monday, February 23rd. Weiss Ratings reaffirmed a “sell (e+)” rating on shares of ImmunityBio in a report on Monday, December 29th. D. Boral Capital reiterated a “buy” rating and set a $23.00 price target on shares of ImmunityBio in a report on Monday, March 23rd. Finally, Jefferies Financial Group upped their price objective on ImmunityBio from $8.00 to $9.00 and gave the company a “buy” rating in a research note on Friday, December 12th. One equities research analyst has rated the stock with a Strong Buy rating, five have given a Buy rating and one has assigned a Sell rating to the company’s stock. According to data from MarketBeat.com, the company has an average rating of “Moderate Buy” and an average target price of $14.40.

ImmunityBio Trading Up 2.2%

The company has a market cap of $7.51 billion, a price-to-earnings ratio of -19.21 and a beta of 0.13. The business’s 50 day moving average price is $7.73 and its 200-day moving average price is $4.33.

ImmunityBio (NASDAQ:IBRX) last announced its quarterly earnings results on Monday, February 23rd. The company reported ($0.06) EPS for the quarter, beating analysts’ consensus estimates of ($0.08) by $0.02. The company had revenue of $38.29 million during the quarter. Equities research analysts forecast that ImmunityBio, Inc. will post -0.92 EPS for the current fiscal year.

Insider Activity at ImmunityBio

In related news, Director Christobel Selecky sold 25,000 shares of the business’s stock in a transaction on Monday, February 23rd. The stock was sold at an average price of $10.00, for a total value of $250,000.00. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, Director Barry J. Simon sold 75,000 shares of the company’s stock in a transaction on Tuesday, February 24th. The shares were sold at an average price of $12.01, for a total value of $900,750.00. Following the completion of the transaction, the director directly owned 2,850,821 shares in the company, valued at approximately $34,238,360.21. This represents a 2.56% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. Over the last three months, insiders have sold 501,967 shares of company stock valued at $4,466,412. 69.48% of the stock is currently owned by insiders.

Hedge Funds Weigh In On ImmunityBio

Several institutional investors and hedge funds have recently modified their holdings of IBRX. AQR Capital Management LLC lifted its holdings in shares of ImmunityBio by 193.4% during the 1st quarter. AQR Capital Management LLC now owns 44,448 shares of the company’s stock worth $134,000 after acquiring an additional 29,297 shares during the period. PNC Financial Services Group Inc. increased its holdings in ImmunityBio by 1,104.4% in the second quarter. PNC Financial Services Group Inc. now owns 13,815 shares of the company’s stock valued at $36,000 after purchasing an additional 12,668 shares during the period. Creative Planning raised its position in ImmunityBio by 9.2% during the 2nd quarter. Creative Planning now owns 62,028 shares of the company’s stock worth $164,000 after purchasing an additional 5,231 shares during the last quarter. Cetera Investment Advisers raised its position in ImmunityBio by 56.9% during the 2nd quarter. Cetera Investment Advisers now owns 18,551 shares of the company’s stock worth $49,000 after purchasing an additional 6,731 shares during the last quarter. Finally, Swiss National Bank lifted its holdings in ImmunityBio by 2.7% during the 2nd quarter. Swiss National Bank now owns 421,500 shares of the company’s stock worth $1,113,000 after buying an additional 11,100 shares during the period. 8.58% of the stock is currently owned by institutional investors and hedge funds.

ImmunityBio Company Profile

ImmunityBio, Inc is a clinical-stage biotechnology company specializing in the development of novel immunotherapies for cancer and infectious diseases. The company’s research platform centers on harnessing the power of the human immune system—through engineered T cells, natural killer (NK) cells, cytokine superagonists and viral-vectored vaccines—to target and eliminate diseased cells across a range of indications.

Among its lead assets is Anktiva (formerly known as N-803), an interleukin-15 superagonist designed to stimulate NK and T cell activity.